Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accounts Payables: 2009-2024

Historic Accounts Payables for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $13.9 million.

  • Cumberland Pharmaceuticals' Accounts Payables rose 14.72% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 14.72%. This contributed to the annual value of $13.9 million for FY2024, which is 0.88% down from last year.
  • According to the latest figures from FY2024, Cumberland Pharmaceuticals' Accounts Payables is $13.9 million, which was down 0.88% from $14.0 million recorded in FY2023.
  • In the past 5 years, Cumberland Pharmaceuticals' Accounts Payables registered a high of $14.0 million during FY2023, and its lowest value of $9.6 million during FY2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Accounts Payables averaged around $12.9 million, with its median value being $13.9 million (2024).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Accounts Payables soared by 34.05% in 2020, and later fell by 28.03% in 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' Accounts Payables (Yearly) stood at $13.4 million in 2020, then decreased by 28.03% to $9.6 million in 2021, then increased by 12.22% to $10.8 million in 2022, then grew by 29.75% to $14.0 million in 2023, then decreased by 0.88% to $13.9 million in 2024.